Genetics

Tango Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Highlights

Retrieved on: 
Wednesday, May 8, 2024
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, Clinical Trials, FXI, MTAP, Mutation, Safety, PARP, Pharmacokinetics, Carcinoma, Breast, STK11, BID, GBM, Glioblastoma, Culture, Journal, Novartis, Patient, Medicinal chemistry, Cancer, Collaboration, Clinical trial, Therapy, NSCLC, PRMT5, Pharmaceutical industry

Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, reported its financial results for the first quarter ended March 31, 2024, and provided business highlights.

Key Points: 
  • Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, reported its financial results for the first quarter ended March 31, 2024, and provided business highlights.
  • Finally, we welcomed the newest member of our leadership team, Julie Carretero, as Chief Human Resources Officer.
  • Dose expansion is expected to initiate in the TNG462 phase 1/2 clinical trial in 2Q 2024.
  • General and administrative expenses were $10.7 million for the three months ended March 31, 2024, compared to $8.0 million for the same period in 2023.

Neurenati Therapeutics Strengthens Its Board of Directors With the Appointment of Dr. Marielle Cohard-Radice

Retrieved on: 
Wednesday, May 8, 2024
Health, Genetics, Other Health, Research, Science, Pharmaceutical, Biotechnology, B cell, Enteric nervous system, DevOps, IRIC, Therapy, Molecule, Daiichi Sankyo, Hirschsprung's disease, Management

Neurenati Therapeutics, a pediatric rare diseases-focused company, is delighted to announce the appointment of a highly-experienced executive in the pharma industry as an independent board member.

Key Points: 
  • Neurenati Therapeutics, a pediatric rare diseases-focused company, is delighted to announce the appointment of a highly-experienced executive in the pharma industry as an independent board member.
  • Dr Marielle Cohard-Radice is a gastroenterologist who held various executive positions in several therapeutic areas over three decades.
  • Welcome on the board of directors,” added Maxime Ranger, CEO of Neurenati.
  • Looking forward to supporting Neurenati in its efforts,” said Dr. Cohard-Radice
    Both independent board members, Dr Alexandre Lebeaut and Dr Marielle Cohard-Radice will assist Neurenati to create its scientific and clinical advisory board in upcoming months.

Largest Prospective Study to Date Further Supports Performance of DecisionDx®-UM for Metastatic Risk Stratification in Uveal Melanoma and Utility of PRAME Biomarker for Refining Risk When Considered with DecisionDx-UM Class Result

Retrieved on: 
Wednesday, May 8, 2024
Research, Genetics, Clinical Trials, Biometrics, Biotechnology, General Health, Health, Optical, Science, Oncology, Bascom Palmer Eye Institute, University, Risk, MFS, PRAME, Glomus tumor, Patient, Eye, Metastasis, Uveal melanoma, Annual general meeting, ARVO, UM, Medical imaging

Further, the study provides prospective validation data supporting Preferentially Expressed Antigen in Melanoma (PRAME) as a risk refinement tool when considered in the context of a Class 1 or Class 2 DecisionDx-UM test result.

Key Points: 
  • Further, the study provides prospective validation data supporting Preferentially Expressed Antigen in Melanoma (PRAME) as a risk refinement tool when considered in the context of a Class 1 or Class 2 DecisionDx-UM test result.
  • The data was presented at the Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting in Seattle.
  • “The study data provides support for combining the reported expression status of the PRAME gene with the DecisionDx-UM class result to enhance metastatic risk prediction.
  • Patients with Class 2 tumors had considerably worse outcomes than those with Class 1 tumors, regardless of PRAME status; however, PRAME+ tumors fared worse within each GEP class (versus PRAME-).

Obsidian Therapeutics Appoints Dana Alexander as Chief Technical Officer

Retrieved on: 
Wednesday, May 8, 2024
Biotechnology, Health, Genetics, Pharmaceutical, Oncology, Obsidian, Boston University, Chemical engineering, TIL, Senior, Chemistry, CMC, Therapy, Thermo Fisher Scientific

Obsidian Therapeutics, Inc., a clinical-stage biotechnology company pioneering engineered cell and gene therapies, today announced the appointment of Dana Alexander as Chief Technical Officer.

Key Points: 
  • Obsidian Therapeutics, Inc., a clinical-stage biotechnology company pioneering engineered cell and gene therapies, today announced the appointment of Dana Alexander as Chief Technical Officer.
  • “Dana has over two decades of operational expertise across cell therapy, gene therapy and biologics process development and chemistry, manufacturing, and controls (CMC), from Phase 1 through commercialization,” said Madan Jagasia, M.D., Chief Executive Officer of Obsidian.
  • We are delighted to welcome Dana to our management team.”
    “I am thrilled to be joining the highly accomplished and passionate Obsidian leadership team and to have the opportunity to grow and expand the company’s CMC capabilities,” said Mr. Alexander.
  • Previously, Mr. Alexander held roles as Vice President of Operations, Viral Vector Services at Thermo Fisher Scientific (Brammer Bio) and Chief Operations Officer at Anika Therapeutics.

Personalis Reports First Quarter 2024 Financial Results

Retrieved on: 
Wednesday, May 8, 2024
Biotechnology, Health, Genetics, Pharmaceutical, Oncology, NeXT, Neoplasm, Cancer, Total, Genomics, Investment, PSNL, MRD, Colorectal cancer, Abstract, Recurrence, PPM, Patient, Society, Medicare, Breast cancer

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the first quarter of 2024 ended March 31, 2024, and provided recent business highlights.

Key Points: 
  • Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the first quarter of 2024 ended March 31, 2024, and provided recent business highlights.
  • The analytical validation for the company’s NeXT Personal MRD test was published in Oncotarget on March 14, 2024.
  • NeXT Personal is the first-to-market ultra-sensitive minimal residual disease (MRD) assay to detect cancer, and monitor therapy response in patients with solid tumor cancers.
  • A replay of the webinar will be available shortly after the conclusion of the call and will be archived on the company's website.

AdvanCell Expands Leadership Team with the Appointment of Christopher Horvath, MS MBA, as Chief Commercial Officer & Chief Operating Officer and Gary Li, PhD, as Chief Strategy Officer

Retrieved on: 
Wednesday, May 8, 2024
Radiology, Pharmaceutical, Optical, Oncology, Mental Health, Medical Devices, Infectious Diseases, Genetics, Fitness & Nutrition, Clinical Trials, Cardiology, Biotechnology, Alternative Medicine, Health, Practice Management, Managed Care, General Health, Nursing, Medical Supplies, FDA, Diabetes, Surgery, Other Health, Cancer, Commercial, EVP, Johnson & Johnson, Doctor of Philosophy, Janssen, Prostate cancer, SVP, Pfizer, Patient, Translational medicine, Radiopharmaceutical, MBA, Drug discovery, Merck, Management

Chris Horvath, MS, MBA - Chief Commercial and Operating Officer based in Philadelphia.

Key Points: 
  • Chris Horvath, MS, MBA - Chief Commercial and Operating Officer based in Philadelphia.
  • Chris brings nearly two decades of biopharmaceutical oncology expertise spanning drug discovery, commercialization, and corporate leadership, to AdvanCell.
  • Over the past eight years, Chris has been responsible for commercial strategy and leadership, launch preparation and execution, and revenue growth of both clinical-stage and commercial radiopharmaceuticals in oncology.
  • Most recently, at POINT Biopharma, he served as EVP, Commercial and managed cross-functional alliance operations with Lantheus for two clinical-stage assets.

Biodesix Announces First Quarter 2024 Results Driven by Growth in Lung Diagnostic Testing for Lung Nodule Management

Retrieved on: 
Wednesday, May 8, 2024
Radiology, Pharmaceutical, Research, Oncology, Software, Medical Devices, Hospitals, Genetics, Data Management, Stem Cells, Science, Practice Management, Technology, Clinical Trials, Medical Supplies, FDA, Biotechnology, Surgery, Health, CO, Cancer, Depreciation, Webcast, DdPCR, Forecasting, Growth, MSKCC, Net operating loss, Patient, COVID-19, Acquisition, Adjustment, AACR, Bank statement, EGFR, GAAP, AstraZeneca

In the first quarter, we delivered approximately 11,900 Lung Diagnostic tests, an increase of 57% over the prior year comparable period and our seventh consecutive quarter of greater than 50% year-over-year volume growth.

Key Points: 
  • In the first quarter, we delivered approximately 11,900 Lung Diagnostic tests, an increase of 57% over the prior year comparable period and our seventh consecutive quarter of greater than 50% year-over-year volume growth.
  • Our team is off to a strong start, helping to impact more patients every quarter in the large and underserved lung nodule diagnostic testing market.
  • Record quarterly gross profit margin of 79% versus 65% for the first quarter 2023 and 77% for the fourth quarter of 2023.
  • The Company reaffirms its 2024 financial outlook and expects to generate between $65 million and $68 million in total revenue in 2024.

Precision BioSciences Announces Common Stock Purchase by Members of Management for $300,000 in a Private Placement

Retrieved on: 
Wednesday, May 8, 2024
Science, Biotechnology, Research, Pharmaceutical, Health, Infectious Diseases, Genetics, Clinical Trials, Private placement, Sale, Private, Precision BioSciences, Gene editing, News, Security (finance)

The Private Placement is expected to close on May 8, 2024, subject to the satisfaction of customary closing conditions.

Key Points: 
  • The Private Placement is expected to close on May 8, 2024, subject to the satisfaction of customary closing conditions.
  • The Company intends to use the net proceeds from this offering to support its ongoing research and development initiatives.
  • There is no placement agent for the Private Placement.
  • The offer and sale of the securities have not been, and will not be, registered under the Securities Act of 1933, as amended, or any other securities laws.

Twist Bioscience Corporation Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Retrieved on: 
Wednesday, May 8, 2024
Biotechnology, Health, Genetics, Pharmaceutical, Health Technology, Silicon, Vesting, Employment, Graduation

As required by the rules of the Nasdaq Stock Market, Twist Bioscience Corporation (NASDAQ: TWST) (“Twist” or the “Company”), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it has granted a total of 87,200 restricted stock units (“RSUs”) to 26 recently hired individuals as an inducement material to their acceptance of employment with Twist.

Key Points: 
  • As required by the rules of the Nasdaq Stock Market, Twist Bioscience Corporation (NASDAQ: TWST) (“Twist” or the “Company”), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it has granted a total of 87,200 restricted stock units (“RSUs”) to 26 recently hired individuals as an inducement material to their acceptance of employment with Twist.
  • The employment inducement awards were granted under Twist’s Inducement Equity Incentive Plan and related form of restricted stock award agreement in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The inducement plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Twist, or following a bona fide period of non-employment, as an inducement material to such individuals entering into employment with Twist, pursuant to Nasdaq Listing Rule 5635(c)(4).
  • The RSUs vest over a 48-month period for each employee as follows: 25% vests on the one year anniversary of the start date of the employee (the “Vesting Commencement Date”), and 1/16 of the RSUs vest on each quarterly anniversary (or the last day of the month if no such day exists) of the Vesting Commencement Date thereafter, subject to the employee’s continued service through each vesting date.

Precision BioSciences to Report First Quarter Results on May 13, 2024

Retrieved on: 
Tuesday, May 7, 2024
FDA, Other Health, Technology, Nanotechnology, Stem Cells, Pharmaceutical, Infectious Diseases, Genetics, Fitness & Nutrition, Clinical Trials, Science, Biotechnology, Other Science, Health, Research, Gene editing, Precision BioSciences

Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, today announced that it will publish financial results for the first quarter 2024 and provide a business update on Monday, May 13, 2024.

Key Points: 
  • Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, today announced that it will publish financial results for the first quarter 2024 and provide a business update on Monday, May 13, 2024.